Straits Times Index
3,323.39 +9.25 (+0.28%) Nikkei
39,150.62 +345.97 (+0.89%) Hang Seng
18,128.62 +100.91 (+0.56%) FTSE 100
8,281.55 +43.83 (+0.53%) Bitcoin USD
60,984.66 -1,336.82 (-2.15%) CMC Crypto 200
1,271.88 -37.84 (-2.89%)
ONVO Sep 2024 5.000 call
| Previous close | 0.5500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 5.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.5500 - 0.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireOrganovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company’s lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and p
- GlobeNewswire
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024. The post
- GlobeNewswire
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its
